ARTICLE | Clinical News
Isentress raltegravir regulatory update
October 29, 2012 7:00 AM UTC
EMA's CHMP recommended expanding the label for Merck's Isentress raltegravir to treat HIV-1 infection in combination with other antiretroviral therapies to include treatment of patients ages 2-18 year...